WearLinq Announces Acquisition of AMI Cardiac Monitoring, LLC, and Expands Clinical Services Nationwide with FDA 510(k) Cleared 6-Lead ECG Device
May 21 2024 - 8:15AM
Business Wire
WearLinq, a leading provider of wearable health monitoring and
diagnosis solutions, today announced the acquisition of AMI Cardiac
Monitoring, LLC, an established independent diagnostic testing
facility (IDTF) with more than 33 years of expertise in ambulatory
cardiac monitoring. This strategic acquisition will fuel WearLinq’s
capacity to offer expansive clinical services across all 50 states
and provide more patients access to its eWave 6-lead wearable ECG
monitor, which recently received FDA 510(k) clearance. This
announcement comes on the heels of a successful close of $6.7
million in early-stage investment from SpringTide, Social Impact
Capital, Amino Capital, Berkeley Catalyst Fund, Human Longevity and
angels from iRhythm and AliveCor.
“The astute clinical capabilities of AMI combined with the
advanced technology of WearLinq will create a tremendously
productive partnership,” said Konrad Morzkowski, CEO of WearLinq.
“AMI and WearLinq share the same values and visions of providing
excellent services for patients and clinical facilities. This
synergy enhances our ability to deliver comprehensive cardiac
diagnostics, promising significant advancements in healthcare
services for cardiac patients and will undoubtedly position us as
market leaders very soon.”
One in three people will develop atrial fibrillation (AFib)
during their lifetime. AFib increases the risk of stroke fivefold
and most commonly leads to heart failure. The current standard of
care leaves many patients undiagnosed and untreated, with over 30%
receiving false negatives and re-testing within 6 months. In
response, WearLinq has built the best diagnostic solution to
address these challenges.
The eWave 6-lead ECG device by WearLinq marks a significant
technological leap in ambulatory cardiac monitoring, providing
cardiologists with a detailed, multidimensional view of the heart,
ensuring P-wave visibility and exceptional ECG clarity. It works
with the patient’s smartphone, allowing for long-term monitoring
with convenient recharging in an AirPods-like case and magnetically
attaches to WearLinq's skin-like (patent pending) adhesive
patches.
“We are excited to join forces with WearLinq, a company at the
forefront of cardiac monitoring innovation. This partnership aligns
perfectly with our mission to provide exceptional diagnostic
services,” said Dorothy Glodek, Founder of AMI Cardiac Monitoring,
LLC. “By integrating WearLinq’s advanced 6-lead ECG technology with
our extensive clinical expertise, we can offer unparalleled cardiac
care to patients nationwide. Together, we are set to revolutionize
the field of ambulatory cardiac monitoring, ensuring more accurate
diagnoses and improved patient outcomes.”
Designed with patient comfort and clinical accuracy in mind, the
WearLinq ECG device is wearable and minimally intrusive. It allows
patients to maintain their lifestyle while continuously monitoring
their cardiac health. Integrated with a state-of-the-art cloud
platform, the device ensures near real-time data analysis and
actionable insights for healthcare providers.
“This is just the beginning; we have an exciting pipeline of AI
products to further empower patients and providers, as well as take
our reach beyond cardiac monitoring,” adds Morzkowski. “We are
dedicated to continuous innovation and expanding our impact across
the healthcare spectrum.”
Additionally, industry veteran Joe Knight, joint inventor of
iRhythm’s ZioPatch, has joined WearLinq’s Board of Directors.
For more information about WearLinq and its innovative
solutions, please visit wearlinq.com.
About WearLinq
WearLinq is a leading provider of health monitoring and
diagnosis solutions, dedicated to enhancing patient care and
clinical outcomes. With a focus on harnessing cutting-edge
technology and providing actionable insights, WearLinq is set to
elevate the standard of care.
About AMI Cardiac Monitoring, LLC
AMI Cardiac Monitoring, LLC is a leading provider of ambulatory
heart monitoring services and diagnostic technologies across the
United States. With over 30 years of experience, AMI Cardiac
Monitoring is committed to enhancing patient outcomes by delivering
accurate, timely, and actionable cardiac data. Our state-of-the-art
diagnostic tools and dedicated support team ensure healthcare
providers can offer exceptional care to patients experiencing
cardiac issues. AMI Cardiac Monitoring continues to set industry
standards in reliability, innovation, and patient care. For more
information, please visit www.amicardiac.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240521325743/en/
Josh Heath josh@springtide.com